The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Serum Amyloid P Therapeutically Attenuates Murine Bleomycin-Induced Pulmonary Fibrosis via Its Effects on Macrophages
Open accessAbstract
Macrophages promote tissue remodeling but few mechanisms exist to modulate their activity during tissue fibrosis. Serum amyloid P (SAP), a member of the pentraxin family of proteins, signals through Fcgamma receptors which are known to affect macrophage activation. We determined that IPF/UIP patients have increased protein levels of several alternatively activated pro-fibrotic (M2) macrophage-associated proteins in the lung and monocytes from these patients show skewing towards an M2 macrophage phenotype. SAP therapeutically inhibits established bleomycin-induced pulmonary fibrosis, when administered systemically or locally to the lungs. The reduction in aberrant collagen deposition was associated with a reduction in M2 macrophages in the lung and increased IP10/CXCL10. These data highlight the role of macrophages in fibrotic lung disease, and demonstrate a therapeutic action of SAP on macrophages which may extend to many fibrotic indications caused by over-exuberant pro-fibrotic macrophage responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Lung macrophages serve as obligatory intermediate between blood monocytes and alveolar macrophages
Landsman, L., & Jung, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3488 · Cited by 258
Reduction of Bleomycin-Induced Pulmonary Fibrosis by Serum Amyloid P
Pilling, D., Roife, D., Wang, M., Ronkainen, S. D., Crawford, J. R., Travis, E. L., & Gomer, R. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.4035 · Cited by 230
Roles of T lymphocytes in pulmonary fibrosis
Luzina, I. G., Todd, N. W., Iacono, A. T., & Atamas, S. P. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0707504 · Cited by 163 · cited 1×
“Moreover, the role of T cells during lung fibrosis is controversial [16] and further studies with potential advances in technology to help delineate the cellular source of IL13 would add to our current understanding.”
BackgroundMechanisms of Oncostatin M-Induced Pulmonary Inflammation and Fibrosis
Mozaffarian, A., Brewer, A. W., Trueblood, E. S., Luzina, I. G., Todd, N. W., Atamas, S. P., & Arnett, H. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7243 · Cited by 153
Cited by
Macrophage plasticity and polarization in tissue repair and remodelling
Mantovani, A., Biswas, S. K., Galdiero, M. R., Sica, A., & Locati, M. (2013) · The Journal of Pathology · doi:10.1002/path.4133 · Cited by 2,384
Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span
Misharin, A. V., Morales-Nebreda, L., Reyfman, P. A., Cuda, C. M., Walter, J. M., McQuattie-Pimentel, A. C., Chen, C.-I., Anekalla, K. R., Joshi, N., Williams, K. J. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162152 · Cited by 1,133
“It has been suggested that polarization of alveolar macrophages toward a profibrotic or “M2” phenotype contributes to the development of fibrosis (Murray et al., 2010; Larson-Casey et al., 2016).”
BackgroundMacrophage polarization in pathology
Sica, A., Erreni, M., Allavena, P., & Porta, C. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1995-y · Cited by 673
Macrophages: Their role, activation and polarization in pulmonary diseases
Arora, S., Dev, K., Agarwal, B., Das, P., & Syed, M. A. (2018) · Immunobiology · doi:10.1016/j.imbio.2017.11.001 · Cited by 639
Host Responses in Tissue Repair and Fibrosis
Duffield, J. S., Lupher, M., Thannickal, V. J., & Wynn, T. A. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163930 · Cited by 624
Macrophages and Tissue Injury: Agents of Defense or Destruction?
Laskin, D. L., Sunil, V. R., Gardner, C. R., & Laskin, J. D. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105812 · Cited by 604
Hepatocytes: a key cell type for innate immunity
Zhou, Z., Xu, M.-J., & Gao, B. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.97 · Cited by 472
Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis
Gibbons, M. A., MacKinnon, A. C., Ramachandran, P., Dhaliwal, K., Duffin, R., Phythian-Adams, A. T., van Rooijen, N., Haslett, C., Howie, S. E., Simpson, A. J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201010-1719oc · Cited by 466
Molecular and cellular mechanisms of pulmonary fibrosis
Todd, N. W., Luzina, I. G., & Atamas, S. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-11 · Cited by 418
TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P
Murray, L. A., Chen, Q., Kramer, M. S., Hesson, D. P., Argentieri, R. L., Peng, X., Gulati, M., Homer, R. J., Russell, T., van Rooijen, N., et al. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.10.013 · Cited by 362
Self-citationThe Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis
Desai, O., Winkler, J., Minasyan, M., & Herzog, E. L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00043 · Cited by 314
Self-citationModeling pulmonary fibrosis with bleomycin
Mouratis, M. A., & Aidinis, V. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328349ac2b · Cited by 311
Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis
Le, T.-T. T., Karmouty-Quintana, H., Melicoff, E., Le, T.-T. T., Weng, T., Chen, N.-Y., Pedroza, M., Zhou, Y., Davies, J., Philip, K., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302470 · Cited by 299
The Role of Macrophages in the Development of Acute and Chronic Inflammatory Lung Diseases
Lee, J.-W., Chun, W., Lee, H. J., Min, J.-H., Kim, S.-M., Seo, J.-Y., Ahn, K.-S., & Oh, S.-R. (2021) · Cells · doi:10.3390/cells10040897 · Cited by 291
Savin, I. A., Zenkova, M. A., & Sen’kova, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314959 · Cited by 279
Cellular interactions in the pathogenesis of interstitial lung diseases
Bagnato, G., & Harari, S. (2015) · European Respiratory Review · doi:10.1183/09059180.00003214 · Cited by 277
The therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
Su, S., Zhao, Q., He, C., Huang, D., Liu, J., Chen, F., Chen, J., Liao, J.-Y., Cui, X., Zeng, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms9523 · Cited by 253
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Mercer, P. F., Woodcock, H. V., Eley, J. D., Platé, M., Sulikowski, M. G., Durrenberger, P. F., Franklin, L., Nanthakumar, C. B., Man, Y., Genovese, F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207429 · Cited by 206
Reilkoff, R. A., Peng, H., Murray, L. A., Peng, X., Russell, T., Montgomery, R., Feghali-Bostwick, C., Shaw, A., Homer, R. J., Gulati, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201206-1109oc · Cited by 135
Self-citationYoung, L. R., Gulleman, P. M., Short, C. W., Tanjore, H., Sherrill, T., Qi, A., McBride, A. P., Zaynagetdinov, R., Benjamin, J. T., Lawson, W. E., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88947 · Cited by 105
The Development of Serum Amyloid P as a Possible Therapeutic
Pilling, D., & Gomer, R. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02328 · Cited by 92
“SAP injections have now been shown to inhibit inflammation and fibrosis in other models of pulmonary fibrosis (102, 103), cardiac fibrosis (96, 97), radiation-induced oral mucositis (101), allergic airway disease (100), autoimmune encephalomyelitis (114), corneal wound healing (75), and two models of renal fibrosis/ e…”
BackgroundProtective effect of human serum amyloid P on CCl4-induced acute liver injury in mice
Cong, M., Zhao, W., Liu, T., Wang, P., Fan, X., Zhai, Q., Bao, X., Zhang, D., You, H., Kisseleva, T., et al. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3028 · Cited by 33
Pilling, D., Cox, N., Thomson, M. A., Karhadkar, T. R., & Gomer, R. H. (2019) · The American Journal of Pathology · doi:10.1016/j.ajpath.2019.08.005 · Cited by 17
Wu, X., Li, W., Luo, Z., & Chen, Y. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02861-w · Cited by 9
Metadata
- Authors
- Murray, L. A., Rosada, R., Moreira, A. P., Joshi, A., Kramer, M. S., Hesson, D. P., Argentieri, R. L., Mathai, S., Gulati, M., Herzog, E. L., & Hogaboam, C. M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-03-12
- Volume
- 5
- Issue
- 3
- Pages
- e9683
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2081253240
- Cited by
- 192
- References
- 6
- FWCI
- 13.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.